Cargando…

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chao, Zhang, Wei, Zhou, Daobin, Zhang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606549/ https://www.ncbi.nlm.nih.gov/pubmed/34820328 http://dx.doi.org/10.3389/fonc.2021.757403

Ejemplares similares

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review
por: Chen, Chao, et al.
Publicado: (2022)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Post-chemotherapy pneumonia in Chinese patients with diffuse large B-cell lymphoma: Outcomes and predictive model
por: Zhao, Jinrong, et al.
Publicado: (2022)

Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review
por: Xu, Qing-Yuan, et al.
Publicado: (2022)

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report
por: Yang, Dan, et al.
Publicado: (2018)

Relapsed/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review
por: Yang, Yuanyuan, et al.
Publicado: (2023)

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up
por: Zhu, Fang, et al.
Publicado: (2020)

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
por: Wei, Chong, et al.
Publicado: (2021)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
por: Song, Kunkun, et al.
Publicado: (2023)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report
por: Xu, Jingyan, et al.
Publicado: (2021)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report
por: Hu, Shaoxuan, et al.
Publicado: (2020)

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review
por: Jin, Jingxia, et al.
Publicado: (2018)

The findings on the CEUS of diffuse large B cell lymphoma in abdomen: A case report and literature review
por: Zhang, Yu-Qing, et al.
Publicado: (2023)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Zhang, Jun, et al.
Publicado: (2018)

Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
por: Yuan, Li, et al.
Publicado: (2021)

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature
por: Ma, Shuzhen, et al.
Publicado: (2020)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Primary diffuse large B-cell non-Hodgkin's lymphoma of the breast—A case report and review of the literature
por: Harb, Ola A., et al.
Publicado: (2018)

Primary Spinal Epidural Diffuse Large B-cell Lymphoma: Case Report and Literature Review
por: Bhardwaj, Prarthna V, et al.
Publicado: (2022)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma
por: Han, Xiao, et al.
Publicado: (2017)

Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
por: Li, Peifeng, et al.
Publicado: (2021)

Secondary Diffuse Large B-cell Lymphoma Mimicking Meningioma
por: Garcia-Grimshaw, Miguel, et al.
Publicado: (2019)

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
por: Qin, Wei, et al.
Publicado: (2021)

Bilateral Primary testicular diffuse large B-CELL lymphoma
por: Trama, Francesco, et al.
Publicado: (2021)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China
por: Wang, Yawen, et al.
Publicado: (2022)

Hematolymphoid tumor of prostate: Diffuse large B cell lymphoma case report
por: Ochirjav, Enkhee, et al.
Publicado: (2023)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2dbprjvcj66v6d689fckss7pa5